Giant Biogene Holding Co. Ltd. (2367) AI Stock Analysis

• Market Cap: HK$33.99B
• Dividend Yield: 1.84%
• Average Volume (3M): 12.22M
• Price to Earnings (P/E): 13.6
• Beta (1Y): 1.21
• Revenue Growth: 36.70%
• EPS Growth: 22.26%
• Country: HK
• Employees: 1,758
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 1.26
• Shares Outstanding: 1,070,904,000
• 10 Day Avg. Volume: 16,417,830
• 30 Day Avg. Volume: 12,220,358
• PEG Ratio: 0.56
• Price to Book (P/B): 6.60
• Price to Sales (P/S): 8.47
• P/FCF Ratio: 26.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$50.18
• Price Target Upside: 55.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$35.00 ▲(8.29% Upside)

Giant Biogene Holding Co. Ltd. has a strong financial foundation with high revenue growth and solid margins, contributing significantly to its score. However, the bearish technical indicators and lack of cash flow data for 2024 pose concerns. The valuation is reasonable, but not compelling enough to offset the technical weaknesses.

Positive Factors

Sustained Revenue Growth

A 57% year-over-year revenue jump reflects structural demand expansion or successful distribution/product scaling. Sustained top-line growth over multiple periods supports reinvestment capacity, makes future margin expansion likelier, and underpins long-term operating leverage.

Very High Profit Margins

Consistently high gross and net margins indicate durable pricing power and efficient cost structure. Such margin cushions protect profitability in cyclical downturns, enable reinvestment, and suggest differentiated product economics versus peers, supporting sustainable free cash generation.

Strong Balance Sheet

An 88% equity ratio and minimal leverage provide resilience to shocks and financial flexibility for capex or M&A without refinancing risk. A 29% ROE shows effective capital deployment, allowing the company to grow while preserving a conservative capital structure over time.

Negative Factors

Missing 2024 Cash Flow Data

Absence of 2024 cash flow figures limits visibility into current operating cash conversion and liquidity trends. That gap weakens assessment of dividend sustainability, capex funding capacity and working capital needs, making forecasted free cash generation less certain.

Rapid Equity Base Increase

A large rise in equity can stem from retained earnings or capital raises; if not matched by proportional return opportunities it may dilute ROE over time. Monitoring deployment is needed because excess equity without high-return projects can compress shareholder returns.

Limited Investor Communication

Lack of recent earnings call disclosures and corporate-event updates reduces forward-looking clarity on strategy, guidance and management priorities. For investors this means less timely insight into execution risks and capital allocation choices, increasing information risk.

Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model

Company Description

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

How the Company Makes Money

Giant Biogene generates revenue primarily through the sale of its biogeneric drugs and therapeutic products. The company's revenue model is centered around the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. Key revenue streams include direct sales of these biogeneric products to hospitals, pharmacies, and healthcare providers, as well as potential licensing agreements with pharmaceutical companies for the distribution of its innovations. Additionally, partnerships with research institutions and collaborations with other biotech firms contribute to its earnings by enhancing product development capabilities and expanding market reach. The company's focus on regulatory approvals and intellectual property protection further strengthens its market position and potential for revenue generation.

Giant Biogene Holding Co. Ltd. Financial Statement Overview

Summary

Giant Biogene Holding Co. Ltd. exhibits strong financial health with impressive revenue growth, high margins, and a solid balance sheet. The company's minimal debt and high equity ratio provide stability. However, the lack of cash flow data for 2024 raises questions about its liquidity trends.

Income Statement

The company has shown strong revenue growth over the years, with a significant increase from 2023 to 2024 (57%). Gross profit margins are consistently high, indicative of strong pricing power and cost management, with the most recent margin at 82%. Net profit margins are robust, reaching 37% in 2024, reflecting efficient operational management. EBIT and EBITDA margins are also strong, underlining operational efficiency.

Balance Sheet

The balance sheet reveals a solid equity position with a high equity ratio of 88% in 2024, indicating financial stability. The debt-to-equity ratio is very low, reflecting minimal leverage risk. Return on equity is impressive at 29%, showcasing effective utilization of shareholders' capital. However, the substantial increase in stockholders' equity warrants monitoring to ensure sustainable returns.

Cash Flow

Cash flow from operations was strong in 2023, although data for 2024 is not available. The free cash flow in 2023 was positive, contributing to the company's liquidity. The free cash flow to net income ratio is healthy at 97.7% in 2023, indicating efficient conversion of earnings into cash. However, the absence of cash flow data for 2024 limits a comprehensive analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.11B	5.54B	3.52B	2.36B	1.55B	1.19B
Gross Profit	5.00B	4.55B	2.95B	2.00B	1.35B	1.01B
EBITDA	2.60B	2.31B	1.78B	1.21B	933.64M	826.02M
Net Income	2.26B	2.06B	1.45B	1.00B	828.13M	826.45M
Balance Sheet
Total Assets	11.29B	8.04B	4.97B	3.14B	7.88B	2.65B
Cash, Cash Equivalents and Short-Term Investments	8.86B	5.86B	3.78B	2.20B	7.26B	1.96B
Total Debt	6.95M	6.71M	2.73M	2.59M	0.00	0.00
Total Liabilities	2.10B	918.14M	602.03M	301.19M	6.86B	2.19B
Stockholders Equity	9.18B	7.11B	4.36B	2.83B	1.02B	458.00M
Cash Flow
Free Cash Flow	1.47B	1.79B	1.42B	778.39M	581.21M	757.79M
Operating Cash Flow	1.83B	2.04B	1.65B	931.64M	692.40M	834.12M
Investing Cash Flow	-688.87M	-1.11B	-527.28M	-858.74M	1.56B	-521.12M
Financing Cash Flow	1.25B	582.95M	51.81M	-5.79B	4.48B	-17.52M

Giant Biogene Holding Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 32.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 32.32 is below the 20-day moving average (MA) of 34.33, below the 50-day MA of 35.16, and below the 200-day MA of 52.07, indicating a bearish trend. The MACD of -0.79 indicates Positive momentum. The RSI at 32.96 is Neutral, neither overbought nor oversold. The STOCH value of 15.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.

Giant Biogene Holding Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6601	74 Outperform	HK$3.12B	14.81	6.65%	5.90%	9.72%	-10.15%
1044	73 Outperform	$32.13B	13.16	10.69%	5.36%	-3.48%	-24.11%
2367	66 Neutral	HK$33.99B	13.58	29.64%	1.84%	36.70%	22.26%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2145	61 Neutral	HK$26.87B	27.47	39.62%	2.53%	20.78%	18.37%
6993	43 Neutral	HK$16.36B	-28.79	-6.08%	5.00%	2.79%	-170.67%
0157	41 Neutral	HK$940.99M	-15.11	-12.38%	―	39.29%	-71.82%

Giant Biogene Holding Co. Ltd. Corporate Events

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

Giant Biogene Holding Co., Ltd. announced that its wholly owned subsidiary Shaanxi Giant Biotechnology has obtained a Medical Device Registration Certificate in China for a new product, the Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, indicated for intradermal injection to improve cheek smoothness. Billed as the world’s first recombinant collagen and sodium hyaluronate composite solution implant approved for this indication, the product expands the company’s collagen-based product portfolio, reinforces its R&D and industrial capabilities, and is expected to open wider market opportunities in skin rejuvenation as the company moves ahead with commercialization efforts to strengthen its leading position in the health and beauty sector.

The most recent analyst rating on (HK:2367) stock is a Hold with a HK$39.50 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene Announces Share Repurchase Plan to Enhance Value

Giant Biogene Holding Co., Ltd has announced its intention to repurchase up to 103,590,400 shares, representing 10% of its issued shares, under a Share Repurchase Mandate approved by shareholders. This move, financed by the company’s own funds, aims to reflect the board’s confidence in the company’s long-term strategy and growth, improve financial indicators like earnings per share, and optimize capital structure. The repurchase will be subject to compliance with relevant regulations, and its implementation will depend on market conditions and the board’s discretion.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.